First results of a phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment of HER2+ LA/MBC.
S. Tjulandin
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline; Novartis; Pfizer; Roche
A. Makhson
No relevant relationships to disclose
J. Gligorov
No relevant relationships to disclose
M. Lichinitser
No relevant relationships to disclose
A. Lluch
Honoraria - Roche
Other Remuneration - Roche
V. Semiglazov
No relevant relationships to disclose
N. Scotto
Employment or Leadership Position - Roche
L. Mitchell
Employment or Leadership Position - Roche
M. Martin
No relevant relationships to disclose